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Abstract
Background: Several neuromuscular blocking (NMB) agents are available for clinical use in
anesthesia. The present study was performed in order to identify preferences and behaviors of
anesthesiologists for using vecuronium, rocuronium or other NMB agents in their clinical practice.
Material and methods: The cross-sectional survey was applied at the Updated Course of the
Colegio Mexicano de Anestesiología performed last year. Of 989, 282 (28.5%) surveys were returned.
Results: Most anesthesiologists were working at both public and private hospitals, performed
anesthetic procedures for hospitalized and ambulatory patients, and anesthetized children as well
as adults. Respondents did not consider mechanomyography as the gold standard method for
neuromuscular monitoring. The T25 was not recognized as a pharmacodynamic parameter that
represents the clinical duration of the neuromuscular block. Most answered that vecuronium
induces less histamine release than rocuronium, had never used any neuromuscular monitor, did
not know the cost of vecuronium and rocuronium, and preferred rocuronium in multiple-sampling
vials and vecuronium in either a vial for single or multiple sampling. Rocuronium was preferred for
emergency surgery in patients with full stomach only. Almost all of anesthesiologists that conserve
the unused drug did it without refrigeration and more than 30% conserve the unused drug in one
syringe for further use.
Conclusion: Vecuronium was preferred for most clinical situations, and the decision for this
choice was not based on costs. Storage of unused drugs without refrigeration in a single syringe for
purpose of future use in several patients represented a dangerous common practice.
Background
Neuromuscular blockade is an important component of
most procedures that require general anesthesia to facili-
tate tracheal intubation and the surgical procedure. Non-
depolarizing neuromuscular blocking (NMB) agents are
usually preferred because of fewer adverse effects than de-
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polarizing drugs [1–3]. According to their chemical struc-
ture, two classes of non-depolarizing NMB agents have
been available for clinical use, the aminosteroidal (pan-
curonium, vecuronium and rocuronium) and benzyliso-
quinoline drugs (atracurium, mivacurium and
cisatracurium). Vecuronium has been used for many years
in the clinical setting whereas rocuronium is available in
Mexico only since 1999 [4]. Rocuronium has a faster on-
set of action than vecuronium [5,6], and its metabolites
by lacking pharmacological effects avoid any residual neu-
romuscular block [7]. These characteristics favor rocuro-
nium as a better alternative than vecuronium. In relation
to the benzilisoquinoline drugs, these type of NMB agents
produce cardiovascular response and clinical evidence of
histamine release even at recommended doses [8,9].
In our country, until 2000 rocuronium was only provided
as an ampoule containing 50 mg/5 mL, and since last year
the pharmaceutical presentation was modified to a vial
containing a similar concentration but allowing multiple
sampling. Whereas vecuronium is available in two phar-
maceutical presentations, a single-sampling ampoule and
a vial allowing multiple sampling. Each of the two presen-
tations has only 4 mg of vecuronium.
It is estimated that 1.4 million of surgical procedures were
performed last year at the IMSS [10], and three million of
surgical procedures are being performed every year by the
Mexican public health care systems [11]. According to cost
obtained from different sources, rocuronium is signifi-
cantly more expensive than vecuronium, therefore, a com-
plete replacement of vecuronium by rocuronium could
result into a significant increase in spending. The present
survey was performed in order to identify the preferences
of anesthesiologists, as primary users, in relation to the
use of rocuronium, vecuronium or other NMB agents.
Material and Methods
The survey, printed in the two sides of one letter-size sheet
of paper, was developed and validated by a group of four
board-certified Mexican anesthesiologists and two epide-
miologists. It was attached to the documents given to the
989 persons inscribed to the Annual Course of the Colegio
Mexicano de Anestesiología (formerly the Sociedad Mexicana
de Anestesiología) performed in July, last year. Conference
participants were encouraged to fill out and return the sur-
vey at the end of each conference day during the three
days of the course. Of 989, 282 (28.5%) surveys were re-
turned. Data from returned surveys was captured in a pre-
designed Microsoft 97®Excel form and reported as the
number of respondents and proportions. In some cases,
numbers could vary according to persons answering any
specific question.
The survey included the following four sections:
Section 1: General information.
1) Your current maximal specialty training is: anesthesiol-
ogist, anesthesiologist with subspecialty training, or an-
esthesiology resident.
2) Have you been practicing anesthesia for < 5, 5 to 10, or
>10 years?
3) Have you been working at a public, private or both
types of health services?
4) Are your anesthetic procedures performed in pediatric,
adults, or mixed patients? If mixed patients was selected,
then the proportion representing the pediatric patients
was asked (<25, 25 to 50, 50 to 75 or >75%).
5) Are your anesthetic procedures performed on ambula-
tory, hospitalized or mixed patients? If a mixed setting
was selected, then the proportion representing the ambu-
latory patients was asked (<25, 25 to 50, 50 to 75 or
>75%).
Section 2: Basic questions on neuromuscular relaxation.
Questions were elaborated with information obtained
from different sources including textbooks [1,12], printed
documents obtained by subscription [13], guidelines [14]
and web-sites [15]. All sources were available in Spanish
language, at any medical library or freely accessed on the
Internet.
6) Neuromuscular relaxants are classified according to:
chemical structure, duration of action, action at the neu-
romuscular junction or you do not know.
7) The pharmacodynamic parameter of T25 represents: the
time to loss the muscular tone, the time to maximal block,
the clinical duration of the neuromuscular block, or you
do not know.
8) Which of the following methods is considered as the
gold standard for neuromuscular monitoring system?
Electromyography, mechanomyography, electrophysiolo-
gy, acceloromyography, or you do not know.
9) Which is the recommended dose of rocuronium for
any patient undergoing an elective surgery? 150, 300, 600,
900, 1200 µg · kg-1 or you do not know.
10) Which produces less histamine liberation: vecuro-
nium, rocuronium, vecuronium and rocuronium in a
similar potency, or you do not know?
Section 3: Clinical practiceBMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/2
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11) In which percentage of daily surgical procedures do
you utilize a neuromuscular blocking drug? In <25, 25 to
50, 50 to 75, or >75%.
12) Do you routinely use any neuromuscular monitoring
system and if so, which method do you use?
13) Vecuronium is available for reconstitution in two
forms, as an ampoule for single sampling or as a multiple
sampling vial. Which one do you prefer?
14) Do you prefer rocuronium as: an ampoule for single
sampling, a vial for multiple sampling, any of these two
forms, or as a different form?
15) Do you know the unitary cost of vecuronium? Yes or
no.
16) Do you know the unitary cost of rocuronium? Yes or
no.
17) Have you ever used rocuronium? Yes or no.
SECTION 4: Preferences among rocuronium, vecuronium
or other neuromuscular relaxant.
Question: Which neuromuscular blocking drug do you
prefer: rocuronium, vecuronium or other NMB agent...?
18) For an ambulatory patient undergoing a surgical pro-
cedure of one to two hours of duration.
19) For a low surgical risk (ASA 1) male patient, aged 19
yr., undergoing a septorhinoplasty.
20) For a female patient, 32 years old, suffering appendi-
citis and undergoing general anesthesia with tracheal in-
tubation for an emergency surgery with full stomach.
21) For a low surgical risk (ASA 1) pediatric patient, 6 yr.
old, undergoing a planned surgical repair of a bilateral in-
guinal hernia of 1.5 h of duration.
SECTION 5: Behaviors in relation to the drug excess after
obtaining one dose of either vecuronium or rocuronium.
22) What do you do with the excess of the neuromuscular
blocking agent after one dose is obtained, to conserve it in
the same syringe, to maintain it in the vial or ampoule, to
conserve it in several syringes, or to discharge it?
23) If you conserve unused drug, do you refrigerate it? Yes
or no.
Results
Of the 282 respondents, 244 (86.5%) were general an-
esthesiologists, 37 (13.1%) were anesthesiologists with
another postgraduate study, and one resident (0.4%).
Most of the anesthesiologists, 231 (81.9%), have been
graduated more than 10 years ago, 41 (14.5%) between 5
to 10 years ago and only 10 (3.5%) have been graduated
less than 5 years ago. Most worked at both public and pri-
vate hospitals [n= 158 (56.0%)], but many worked at a
public hospital only [n= 119 (42.2%)], and few [n= 5
(1.8%)] worked at a private hospital only.
Most of them, 220 (78.0%), answered that they per-
formed anesthetic procedures in children and adult pa-
tients, 62 (22.0%) in adults only and none in children
only. Of the 220 anesthesiologists performing anesthetic
procedures in children and adults, 195 (88.6%) answered
that <25%, 15 (6.8%) that between 25 to 50%, and 10
(4.5%) that >50% of the procedures were performed in
children. Of the 282, 272 (96.5%) performed anaesthetic
procedures for a combination of hospitalized and ambu-
latory patients, while 10 (3.5%) only for hospitalized and
none provided anesthetic procedures exclusively for am-
bulatory patients.
With regard to questions related to basic concepts on neu-
romuscular relaxation, of 282 only 7.8% considered the
mechanomyography as the gold standard to measure the
neuromuscular response (Table 1). Most of respondants
considered that rocuronium 600µgl kg was the recom-
mended dose for an elective surgery. Approximately 40%
answered that T25 was a pharmacodynamic parameter
representing the clinical duration of the neuromuscular
block. Of 280, only 11.4 answered that vecuronium and
rocuronium were similar in relation to histamine release,
and 85.7% and 2.9% answered that either vecuronium or
rocuronium, respectively, induce less histamine release.
Furthermore, 75.5% answered they administrated a neu-
romuscular blocking agent in <25% of patients, 28.1% in
25 to 50%, 3.9% in 50 to 75% and 1.8% in >75% of pa-
tients.
Of the 282 respondents, 277 (98.2%) have never used any
neuromuscular monitor and 45 (16%) have not used ro-
curonium. In relation to the pharmaceutical presentations
of vecuronium and rocuronium, most of the anesthesiol-
ogists preferred rocuronium in a vial for multiple sam-
pling and considered that vecuronium could be presented
either in a vial for single or multiple sampling (Table 2).
Of 281, 249 (88.3%) and 256 (90.8%) did not know the
cost of vecuronium and rocuronium, respectively.
In relation to the clinical cases, rocuronium was preferred
for tracheal intubation of patients undergoing an emer-
gency surgery with full stomach, while vecuronium wasBMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/2
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preferred for all the other situations also including the
pediatric patient (Table 3). Finally, only one third of re-
spondents discharge the drug excess after one dose is ob-
tained, while approximately 25% conserve the excess in a
single syringe for purpose of future use in several patients
(Table 4).
Discussion
A non-conventional form of questionnaire was used for
the present survey. Questions to be answered in a multiple
option format, by a simple yes or no, to complete the an-
swer, or to select more than one response were included
in different sections. However, our results can be widely
supported, e.g. demographic data have also been observed
in two previous surveys performed at the same setting
[16,17]. It is estimated that the public health care covers
approximately 80% of all the Mexican inhabitants [18],
and almost 60% are attended at the Instituto Mexicano del
Seguro Social (IMSS). Therefore, it was expected that most
of the anesthesiologists were working in a combination of
the public and private services. Furthermore, to our
knowledge only two Mexican pediatric hospitals confer
the official certificate of Pediatric Anesthesiologist recog-
nized by the major public health university [19], which in
turn provides the official title. At the Hospital Infantil de
México (HIM) only 1 to 4 residents are graduated each
year. It was therefore expected that general anesthesiolo-
gists attending both pediatric and adult patients were
Table 1: Concepts on neuromuscular monitoring
Correct Wrong Do not know
Which method of neuromuscular monitoring is considered the gold standard? 22 (7.8) 250 (88.7) 10 (3.5)
What does T25 represent? 112 (39.7) 167 (59.2) 3 (1.1)
Which is the recommended dose of Rocuronium undergoing an elective surgery? 217 (77.0) 65 (23.0) -
Which produce more histamine liberation, Rocuronium or Vecuronium? 32 (11.4) 240 (85.7) 8 (2.9)
n (%)
Table 2: Preferences of pharmaceutical presentations for rocuronium and vecuronium
For single use For multiple sampling Either for single or multiple sampling Other form
Vecuronium 4 mg 27 (9.6) 103 (36.5) 96 (52.5) 4 (1.4)
Rocuronium 50 mg 79 (29.1) 156(55.3) 36 (12.8) 8 (2.8)
n (%)
Table 3: Anesthesiologists preferences to use a NMR in different clinical situations.
Vecuronium Rocuronium Either Vecuronium or 
Rocuronium
Other
Ambulatory surgery of 1–2 h of duration 266 (94.6) 10 (3.6) 0 5 (1.8)
Patient 19 years old, undergoing an elective rinoseptumplastia under 
general anesthesia
150 (53.2) 79 (28.0) 40 (14.7) 12 
(4.1)
Patient with full stomach undergoing an emergency surgery under gen-
eral anesthesia
30 (10.7) 160 (56.9) 64 (22.8) 27 
(9.6)
Patient 6 years old, ASA I, undergoing general anesthesia for an elective 
surgery of 1.5 h of duration
161 (57.3) 29 (10.3) 57 (20.3) 34 
(12.1)
N= 281 (100%)BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/2
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dominant. Unfortunately, we could not compare re-
spondents with the general population attending the
course due to the fact that data from the latter were not
available. Finally, the fact that most of the anesthesiolo-
gists had >10 years of clinical practice is positive in rela-
tion that they are attending updated courses. However,
young anesthesiologists are not. This interesting educa-
tional aspect merits further attention in order to stimulate
the recently graduated students to attend the continuing
education courses.
In relation to the aspects considered as basic concepts for
purpose of the study, it is clear that efforts to extend the
knowledge on neuromuscular relaxation should be per-
formed. Despite topics in NMB agents are usually includ-
ed in the course, a more efficient method of
dissemination of these concepts is needed. It is alarming
that practically none of the anesthesiologists answered
that they used any neuromuscular monitoring method.
How are Mexican anesthesiologists assessing the advan-
tages of the new neuromuscular blocking drugs without
the use of any neuromuscular relaxation monitor? Accord-
ing to the results shown in Table 3, the respondents fa-
vored vecuronium in most clinical cases. However, there
was an important remaining group that considered ro-
curonium or either vecuronium or rocuronium as the pre-
ferred NMB agent. Probably preferences are being based
on clinical experience and observations of success and
failure. For example, despite potentially dangerous, Mexi-
can pediatric anesthesiologists have been administering
an elevated dose of bupivacaine by caudal block accord-
ing to a technique described several years ago because it
has been safe and effective in their own clinical experience
[20]. Despite the intensive publicity, we therefore assume
that vecuronium has been replaced by rocuronium in a
small percentage of cases because using the former has
proven to be safe and effective for a long time. However,
we believe that drug promotion to support rational and
safe drug utilization instead of drug choices based on cus-
tom, conservation, or publicity, should be encouraged
and studied in order to prevent an unjustified preference
for using the expensive NMB agents with similar efficacy
than the older and cheaper drugs. Rational use guidelines
can be established for each institution with a direct impact
into improving clinical practice and cost of services at
short and long terms [21]. Furthermore, the availability of
generic drugs may result into a benefit of a high rate of
population with low economic resources [22]. In our
country, vecuronium is available as a generic drug which
in turn is being produced as the potentially best pharma-
ceutical form.
The idea that rocuronium could be used for rapid intuba-
tion was present, even if the anesthesiologists did not
have any method to corroborate it. Vecuronium was con-
sidered to produce higher histamine liberation than ro-
curonium. Some NMB agents can induce histamine
liberation even at recommended doses, e.g. mivacurium
and atracurium [8,9]. However, vecuronium and rocuro-
nium are drugs that practically do not produce histamine
liberation even at high doses [9,23], while rocuronium is
intermediate in its propensity to cause allergy in known
neuromuscular blocking agents reactors compared with
vecuronium [24].
In Mexico, we only speak Spanish and do not have a sec-
ond language. Despite this fact, knowledge of the English
language is being evaluated as a prerequisite for postgrad-
uate studies. However, further improvement is obtained
by entering private courses usually not required in the
workplaces. Therefore, we could hypothesize that infor-
mation is mainly being searched by our colleagues in na-
tional journals or promotional documents provided by
pharmaceutical companies. This topic deserves urgent at-
tention in order to promote the availability of updated
and unbiased information in Mexican journals.
Approximately 75% of our respondents administered a
neuromuscular blocking drug for <25% of surgical proce-
dures. Most of them preferred rocuronium in multiple
sampling presentation while allowing vecuronium to be
presented either in a single or a multiple sampling vial
while ignoring the commercial cost of the two drugs. It is
estimated that 1.4 million of surgical procedures were per-
formed last year at the IMSS [10], and three million of sur-
gical procedures are being performed every year by the
mexican public health care systems [11]. According to cost
obtained from different sources, rocuronium is between
four to seven times more expensive than vecuronium, and
a complete replacement of vecuronium by rocuronium
could result in significant increases in spending. For ex-
ample, it would represent US$30,000 each year at HIM,
an amount equivalent to the annual salary of approxi-
mately 1.8 pediatric anesthesiologists. Therefore, any in-
crement of budgets for exchanging new for old drugs (e.g.
neuromuscular blocking drugs) should be supported by
evidence also based on cost-effectiveness studies and not
only on efficacy studies.
Rocuronium until 2000 was available in a single sampling
vial only. Since last year it is available in a vial for multiple
sampling also containing 50 mg. However, the fact that
only one pharmaceutical presentation is available for
pediatric and adult patients could generate a waste of re-
sources. Furthermore, we considered that rocuronium
only available as 50 mg and vecuronium as 4 mg are fa-
voring to conserve the unused drug in some instances un-
der unsatisfactory conditions, i.e. in a single syringe
without refrigeration. Although rocuronium conserved at
certain ambient conditions is stable for a brief period ofBMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/2
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time, refrigeration is mandatory [6]. However, after the
ampoule is broken it is recommended to waste the unused
drug. Vecuronium, however, can be stored without refrig-
eration until reconstitution is performed although conser-
vation is recommended for a period not longer than 24
hours. This can be easily performed when using the vial
for multiple sampling.
Furthermore, anesthesiologists preferences in relation to
presentation of rocuronium or vecuronium in a vial for
single or multiple samplings was certainly not supported
by cost-saving attitudes because almost none of the re-
spondents knew the cost of either drug. This year one of
the sectors of the IMSS acquired vecuronium for single
sampling (personal communication, Departamento de
Adquisiciones, Delegación 3, IMSS). Despite the fact that
this alternative is more expensive than the multiple sam-
pling option, by being designed for single sampling it can
be argued that it might result in fewer dangerous conser-
vation practices. Since our results suggests that dangerous
conservation practices are being used, we believe that ur-
gent efforts to educate and to inform anesthesiologists in
the correct use of vecuronium and rocuronium are re-
quired.
Economical impact cannot be examined if corrections in
the clinical practice are not performed, e.g. through the
development of guidelines which in turn require partici-
pation of practitioners. Rational use guidelines have been
shown to result in safe, cost-effective improvement in the
provision of analgesia, sedation and neuromuscular
blockade to critical ill patients requiring ventilator man-
agement [21]. Impact of formulary substitution of e.g. gly-
buride for glipizide, two hypoglycemic drugs, has resulted
in significant (approximately 50%) reduction in overall
hospital expenditures [25], and a joint anesthesia-phar-
Figure 1
Practice of anesthesiologists in relation to the drug excess after one dose of the NMB agents is obtained.BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/2
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macy program has produced a cost-saving exceeding
US$950,000 during a 3-year period at an American hospi-
tal [26]. In fact, NMB agents are appropriate targets of
cost-minimization strategies in anesthesia by different ap-
proaches [21,27–31]. Clinical Pharmacology does not for-
mally exists as a postgraduate option in our country, and
only one unit formally devoted to pharmacological re-
search is available at the IMSS. At the HIM, the Depart-
ment of Clinical Pharmacology and the service of
Hospital Pharmacy are available although none of their
personnel is involved in the activities of the Department
of Anesthesiology. Therefore, the lack of such programs in
our country might favor a lack of planned and permanent
programs designed to identify and solve controversies on
drug utilization. For example, drug dispensing by a phar-
macy service directly involved within the anesthesiology
departments might provide the drug doses in one sterile
syringe while the excess is properly conserved.
Finally, according to different surveys some deficiencies
have been identified among Mexican anesthesiologist in-
cluding indication of preoperative fasting periods unnec-
essary prolonged for adult patients [17], transfusional
practices different from international recommendations
[32], and conservation of the NMB agents excess in one sy-
ringe for using it in multiple patients (current study). We
therefore considered that we have a valuable opportunity
to implement alternative programs in order to improve
anesthetic clinical practices and diminish cost of medical
services.
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